Recludix Pharma Announces Upcoming Oral Presentations on Preclinical Data for Oral STAT6 Inhibitor REX-8756 and Topical STAT 1/3 Inhibitors at the Society for Investigative Dermatology (SID) Annual Meeting

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced preclinical data for STAT6 inhibitor REX-8756 and STAT1/3 inhibitors will be highlighted in two oral presentations at the Society for Investigative Dermatology (SID) Annual Meeting taking place May 13-16, 2026, in Chicago, IL. REX-8756 is an oral, potent and selective STAT6 inhibitor being evaluated in an ongoing blinded, placebo-controlled Phase 1 clinical study.

Oral Presentations

Title:	REX-8756 is an oral first-in-class orthosteric STAT6 inhibitor that demonstrates efficacious potential and safety differentiation in a TH2-mediated dermatitis model
Session Title:	Concurrent Minisymposium 12: Translational Studies: Preclinical
Date:	Friday, May 15, 2026
Time:	8:45 – 8:55 a.m. CT

Title:	First-in-class potent and selective dual STAT1/3 inhibitors optimized for topical treatment of dermatologic inflammatory diseases
Session Title:	Concurrent Minisymposium 12: Translational Studies: Preclinical
Date:	Friday, May 15, 2026
Time:	9:15 – 9:25 a.m. CT

About Recludix
Recludix is a clinical-stage company with leading, innovative platform approaches to discover and develop potent and selective inhibitors of challenging protein targets. The company’s management team includes industry veterans with a track record of success, including former leaders of Seagen, Blueprint Medicines, and Lilly. Recludix has developed a unique drug discovery platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. The company is employing this approach first in the development of SH2 domain inhibitors.

Recludix is conducting a Phase 1 study of REX-8756 (also known as SAR448755), an oral inhibitor of STAT6, in a strategic development and commercialization partnership with Sanofi where Recludix has the option to participate in an equal U.S. profit/loss share. Abnormal activation of STAT6 is found in inflammatory diseases, such as atopic dermatitis, asthma, chronic obstructive pulmonary disease and chronic spontaneous urticaria.

Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor for B cell or mast cell-driven I&I diseases, as well as additional discovery programs. Recludix was named a 2024 Fierce 15 biotech company. For more information, please visit the company’s website at https://recludixpharma.com.

Recludix Contacts
Matt Caldemeyer
Chief Business Officer
mcaldemeyer@recludix.com

Alexandra Santos
asantos@wheelhouselsa.com

Aljanae Reynolds
areynolds@wheelhouselsa.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.